More Information on 'Genomictree Inc'

About Genomictree Inc
Genomictree, Inc. was founded in 2000 and listed at KOSDAQ(Korea Securities Dealers Automated Quotation) in 2019. We are specialized in molecular diagnostics to develop and provide DNA methylation biomarker-based non-invasive molecular tests to support effective early detection of cancers and infectious diseases. Genomictree (228760 KOSDAQ) is biomarker-based molecular diagnostic company for early cancer detection. We were founded with the vision of developing innovative biomarker-based in vitro early cancer diagnosis technologies and products to satisfy the unmet needs of healthcare markets, thereby contributing to improving the quality of life for humanity, and the reduction of total medical expenditure. Abnormal DNA methylation is epigenetic mutation that occurs in cancer cells. Our strategy for development and commercialization of early cancer detection technology involves: 1) Efficient discovery of methylation biomarkers using our own biomarker discovery engine, 2) establishment of clinical evidence for early cancer diagnosis to acquire intellectual property rights, 3) development of accurate measuring techniques that are able to detect biomarkers in bodily fluids (liquid biopsy), while maintaining high sensitivity and specificity, and 4) validation of clinical effectiveness and utility with bodily fluids.

Looking for Channel Partners in: